BioEngine was ranked on "2022 CHINA HEALTHCARE INDUSTRY INVESTMENT AND FINANCING HONOR LIST"

Time：Apr 28,2023

On the evening of April 26, China Healthcare Consulting and CITIC Securities officially released the "2022 China Healthcare Industry Investment and Financing Honor List". With its outstanding market performance and industry influence in 2022, BioEngine was ranked as one of the "Top 50 Most Valuable Investment Companies in Healthcare in 2022".

The "China Healthcare Industry Investment and Financing Honor List" is jointly launched by China Healthcare Consulting and CITIC Securities. Through data statistics, horizontal comparison and full-dimensional analysis, the industry participants such as investment institutions, investors and innovative enterprises that have made outstanding contributions to the development and investment and financing of the healthcare industry in the previous year are selected to recognize their value contributions and set industry benchmarks. As an authoritative list leading the trend of investment and financing in China's medical and health industry, this year's Honor List has selected a total of 14 awards in four categories: investment institutions, enterprises, investors and law firms. Through five years of deep plowing, Honor List has become one of the important wind vane for the development of China's medical and health industry and investment and financing.

Return

Let us contact you

We have a professional technical team to provide high quality one-stop cell culture service from process development
and optimization, medium formulation design to medium processing and manufacturing for all biopharmaceutical companies.

If you have any question, please click "Quick Message" and leave your message, we will reply to you as soon as possible.
If anything urgent, please call (86)21-68582660-2792.

Quick Message